Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, AT&S (24/09/2024)

29.09.2024

Marinomed: Marinomed Biotech AG reported positive clinical data for the new moisturizing Carragelose-containing eye drops.  The results of the study show that treatment with Carragelose eye drops for four weeks significantly improves dry eye-related symptoms by 54%. Next to excellent tolerability, patients also reported a significant improvement in Ocular Surface. The eye drops are part of the recent Carragelose portfolio expansion from viral respiratory infections to targeting allergy and dry eyes. The clinical study conducted in Spain investigated for the first time the lubricating and hydrating effectiveness of Carragelose eye drops in patients affected by mild to moderate dry eye syndrome. 28 Patients were exposed to adverse environmental conditions (23°C, 10% relative humidity and airflow) to challenge dry eye symptoms. Treatment was started after the first challenge and lasted 28 days with a dose of one drop per eye, three times daily. After this treatment period, the patients were again exposed to adverse conditions and the effectiveness of the eye drops were assessed compared to the first challenge. The primary endpoint of the study was the improvement of dry eye-related symptoms such as foreign body sensation, burning or stinging, itching, pain, sticky feeling, sensitivity to light or blurred vision.
Marinomed Biotech: weekly performance: 6.76%

AT&S: AT&S CEO Andreas Gerstenmayer reached an agreement with the Nomination Committee to step down from the AT&S AG Executive Board on September 30, 2024. AT&S is a globally leading manufacturer of high-end IC substrates and printed circuit boards.
AT&S: weekly performance: 0.50%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (24/09/2024)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, AT&S (24/09/2024)


29.09.2024, 1741 Zeichen



Marinomed: Marinomed Biotech AG reported positive clinical data for the new moisturizing Carragelose-containing eye drops.  The results of the study show that treatment with Carragelose eye drops for four weeks significantly improves dry eye-related symptoms by 54%. Next to excellent tolerability, patients also reported a significant improvement in Ocular Surface. The eye drops are part of the recent Carragelose portfolio expansion from viral respiratory infections to targeting allergy and dry eyes. The clinical study conducted in Spain investigated for the first time the lubricating and hydrating effectiveness of Carragelose eye drops in patients affected by mild to moderate dry eye syndrome. 28 Patients were exposed to adverse environmental conditions (23°C, 10% relative humidity and airflow) to challenge dry eye symptoms. Treatment was started after the first challenge and lasted 28 days with a dose of one drop per eye, three times daily. After this treatment period, the patients were again exposed to adverse conditions and the effectiveness of the eye drops were assessed compared to the first challenge. The primary endpoint of the study was the improvement of dry eye-related symptoms such as foreign body sensation, burning or stinging, itching, pain, sticky feeling, sensitivity to light or blurred vision.
Marinomed Biotech: weekly performance: 6.76%

AT&S: AT&S CEO Andreas Gerstenmayer reached an agreement with the Nomination Committee to step down from the AT&S AG Executive Board on September 30, 2024. AT&S is a globally leading manufacturer of high-end IC substrates and printed circuit boards.
AT&S: weekly performance: 0.50%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (24/09/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #775: ATX nach US-Wahlen fester, Less Taxes fürs Stammbuch, Top-Tag für Kontron unabhängig von Trump




 

Bildnachweis

Aktien auf dem Radar:Warimpex, Andritz, RBI, Immofinanz, Austriacard Holdings AG, Addiko Bank, Strabag, EuroTeleSites AG, EVN, Mayr-Melnhof, Frequentis, CA Immo, Polytec Group, AT&S, Gurktaler AG Stamm, Linz Textil Holding, Marinomed Biotech, Porr, RWT AG, SBO, Verbund, voestalpine, Oberbank AG Stamm, Zumtobel, Palfinger, Agrana, Amag, Flughafen Wien, OMV, Österreichische Post, Rosenbauer.


Random Partner

AT&S
Austria Technologie & Systemtechnik AG (AT&S) ist europäischer Marktführer und weltweit einer der führenden Hersteller von Leiterplatten und IC-Substraten. Mit 9.526 Mitarbeitern entwickelt und produziert AT&S an sechs Produktionsstandorten in Österreich, Indien, China und Korea und ist mit einem Vertriebsnetzwerk in Europa, Asien und Nordamerika präsent. (Stand 06/17)

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten